A 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis dependent chronic kidney disease patients with elevated serum phosphorous levels, or hyperphosphatemia. Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced results from this study. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology's (ASN) Kidney Week ...
via Medindia Health News More READ
via Medindia Health News More READ
No comments:
Post a Comment